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1. Introduction 
Populations of cells have unique characteristics and gene markers representative of each cell 
type, and these features are useful for identifying cell characteristics. For example, the gene 
expression profile of cells differs at each stage of development and differentiation. This 
review focuses on gene expression in stem and cancer cells to investigate the possibility of 
identifying cancer stem cells by such markers.  
Cancer stem cells show similarities to normal stem cells in terms of self-renewal and 
differentiation into multiple lineages. However, cancer stem cells have an indefinite 
potential for self-renewal that leads to malignant tumorigenesis. The origins of cancer stem 
cells are not completely clear but accumulation of gene mutations and cell niches are 
involved in their development. This article describes the gene expression patterns of stem 
and cancer cells with the aim of determining gene markers for diverse cell types and culture 
stages for quality control in cellular therapeutics. 
2. The microarray quality control (MAQC) projects 
Stem cells have varied gene and protein expression profiles and it is important to identify 
these profiles for quality control in disease treatment, as illnesses such as cancer may cause 
cell feature changes. The differentiation capacity of stem cells might be altered upon 
malignancy and there is the possibility that cancer comes from so-called cancer stem cells. 
Several methods are available to detect cell marker expression, such as surface protein 
marker detection, intracellular protein marker detection, and gene expression detection. The 
MAQC project, which is a collaborative effort conducted as part of the US Food and Drug 
Administration’s Clinical Path Initiative for medical product development is useful to detect 
gene markers in cells (MAQC Consortium, 2006, 2010; Fan et al., 2010; Oberthuer et al., 2010; 
Huan et al., 2010; Luo et al., 2008; Parry et al., 2010; Shi et al., 2010; Miclaus et al., 2010; Hong 
et al., 2010; Tillinghast, 2010). It began in February 2005 and aims to describe the reliability 
and evaluate the performance of microarrays on several platforms.  
MAQC-I mainly focuses on the technical aspects of gene expression analysis, whereas 
MAQC-II focuses on developing accurate and reproducible multivariate gene expression-
based prediction models. Possible uses for gene expression data are vast, including 
diagnosis, early detection (screening), monitoring of disease progression, risk assessment, 
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prognosis, complex medical product characterisation and prediction of responses to 
treatment (with regard to safety or efficacy) with a drug or device labelling intent.  
The MAQC-II data model prediction is dependent upon endpoints, including preclinical 
toxicity, breast cancer, multiple myeloma and neuroblastoma. Some endpoints are highly 
predictive based on the nature of the data, and other endpoints are difficult to predict 
regardless of the model development protocol. Clear differences in proficiency exist 
between data analysis teams, and such differences are correlated with the level of team 
experience. The internal validation performance from well-implemented, unbiased cross-
validation analyses shows a high degree of concordance with the external validation 
performance in a strictly blinded process, and many models with similar performance can 
be developed from a given data set (Table 1).  
 
 MAQC-I MAQC-II 
Aim 
To address the concerns 
about the reliability of 
microarray techniques 
To develop and evaluate accurate and 
reproducible multivariate gene 
expression-based predictive model 
Summary 
The technical performance of 
microarrays as assessed in 
the project supports their 
continued use for gene 
expression profiling in basic 
and applied research and 
may lead to their use as a 
clinical diagnostic tool as 
well. 
1) Model prediction performance was 
endpoint dependent. 
2) There are clear differences in 
proficiency between data analysis teams 
(organisations). 
3) The internal validation performance 
from well-implemented, unbiased cross-
validation shows a high degree of 
concordance with the external validation 
performance in a strict blinding process. 
4) Many models with similar 
performance can be developed from a 
given data set. 
5) Application of good modelling 
practices appeared to be more important 
than the actual choice of a particular 
algorithm over the others within the 
same step in the modelling process. 
Reference 
MAQC Consortium (2006). 
The MicroArray Quality 
Control (MAQC) project 
shows inter- and 
intraplatform reproducibility 
of gene expression 
measurements, 
Nature Biotechnology, 
Vol.24, No.9, (September 
2006), pp.1151-1161 
MAQC Consortium (2010). The 
MicroArray Quality Control (MAQC)-II 
study of common practices for the 
development and validation of 
microarray-based predictive models, 
Nature Biotechnology, Vol.28, No.8, 
(August 2010), pp.827-838 
Table 1. The Microarray Quality Control (MAQC) projects 
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Applying good modelling practice seems to be more important than the actual choice of a 
particular algorithm over the others within the same step in the modelling process. The 
order of the analysis process was as follows: design, pilot study or internal validation, and 
pivotal study or external validation. Observations based on an analysis of the MAQC-II 
dataset may be applicable to other diseases. (MAQC Consortium, 2010) 
3. Gene markers for stem cells 
3.1 Cell surface marker genes  
The stem cell expression profile varies in differentiated cells. The expression pattern may 
change depending on differentiation or malignancy of the disease. Endothelial cells in 
glioblastomas have unique gene expression profiles, and the differences between 
glioblastomas and lower grade gliomas suggest a more complex ontogeny of the 
glioblastoma endothelium (Wang et al., 2010). Quantitative in situ hybridisation analyses 
have revealed that fluorescence-activated cell-sorted CD105+ (one of the human endothelial 
markers) cells with more than 3 copies of the epidermal growth factor receptor (EGFR) 
amplicon or the centromeric portion of chromosome 7 are similar to the proportion of 
tumour cells with similar aberrations. CD133 is a cell surface glycoprotein, which has been 
used as a possible cancer stem cell marker. CD133 is also expressed in haematopoietic stem 
cells. 
3.2 Genes for mesenchymal stem cells 
3.2.1 Genes expressed in mesenchymal stem cells 
CD29, CD44, CD49a–f, CD51, CD54, CD71, CD73, CD90, CD105, CD106, CD166, Stro-1 and 
MHC class I molecules are positively expressed in human bone marrow derived 
mesenchymal stem cells (MSCs), whereas CD11b, CD14, CD18, CD19, CD31, CD34, CD40, 
CD45, CD56, CD79α, CD80, CD86 and HLA-DR are not (Chamberlain et al., 2007; Kuroda et 
al., 2010; Pittenger et al., 1999; Kumar et al., 2008; Tsai et al., 2007) (Table 2). Specific markers 
for MSCs have not been identified. A combination of gene markers may be important to 
characterise the features of MSCs. 
3.2.2 Genes representing the mesenchymal stem cell culture stage 
MSCs are often used for treating graft-versus-host disease (GVHD) (Weng et al., 2010; Le 
Blanc et al., 2008), suggesting that an infusion of MSCs may be an effective therapy for 
patients with steroid-resistant acute GVHD. The necdin homologue (mouse) (NDN), EPH 
receptor A5 (EPHA5), nephroblastoma overexpressed gene (NOV) and runt-related 
transcription factor 2 (RUNX2) are possible markers to describe culture status, including 
growth capacity and differentiation (Tanabe et al., 2008). EPHA5 and NOV are upregulated 
in late culture stage of human MSCs, whereas NDN and RUNX2 are downregulated (GEO 
series, Tanabe et al., 2008, accession GSE7637 and GSE7888).  
NOV expression in prostate cancer tends to be involved in cancer conditions, based on 
human prostate cancer gene expression data (Best et al., 2005). This expression is 
upregulated in androgen-independent primary human prostate cancer compared to 
untreated human prostate cancer (GEO series, Best, 2005, accession GSE2443). NOV might 
be a candidate marker for identifying the cancer state.  
Human MSCs have been reported to promote growth of osteosarcomas, a common primary 
malignant bone tumour (Bian et al., 2010). In addition, interleukin-6 plays an important role 
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in maintaining the ‘stemness’ of human MSCs and the proliferation of Saos-2. It is possible 
that the secretion of interleukin-6 and interaction of human MSCs and Saos-2 through 
interleukin-6 are essential for their proliferation; this suggests that humoural factors 
participate in stem cell development. 
 
 positive negative 
Human 
MSC 
CD29, CD44, CD49a–f, 
CD51, CD54, CD71, CD73, 
CD90, CD105, CD106, 
CD166, Stro-1 and  
MHC class I molecules 
CD11b, CD14, CD18, 
CD19, CD31, CD34, CD40, 
CD45, CD56, CD79α, 
CD80, CD86, HLA-DR 
Table 2. Positive and negative human mesenchymal stem cell genes  
3.3 Marker genes in neural stem cells 
Glial fibrillary acidic protein (GFAP), Musashi, nestin, excitatory amino acid transporter 1 
(GLAST), PDGFR-α and CD133 are known to be expressed in neural stem cells and are 
generally used as their markers (Yadirgi & Marino, 2009; Jackson & Alvarez-Buylla, 2008; 
Gage, F.H., 2000). The expression of nestin, Dlx2, DVC, PSA-NCAM and βIII tubulin has 
been reported to be altered during cell development. Another report has shown that Sox2, 
which is believed to be a marker of the nervous system, is expressed in embryonic neural 
stem cells and other multipotent cells, and that it plays an essential role in mouse brain 
neurogenesis (Ferri et al., 2004). 
Recently, it had been revealed that glia have the ability to act as stem cells (Robel et al., 
2011). In this study, GFAP, vimentin, nestin, tenascin-C (TNC) and brain lipid-binding 
protein (BLBP) are described as immature markers; whereas, glycogen granules, glutamine 
synthetase, S100β, GLAST and excitatory amino acid transporter 2 (GLT1), which is 
involved in glutamate uptake and conversion to glutamine, are indicated to be common 
glial markers. GLAST and GLT1 are shared markers in astrocytes, radial glial in the 
developing central nervous system, and neural stem cells in the adult mammalian brain. 
GFAP, S100β and aldehyde dehydrogenase 1 family, member L1 (ALDL1H1) are expressed 
in both astrocytes and neural stem cells. 
4. Genes for reprogramming stem cells  
Recent findings have indicated that a set of 4 genes such as POU class 5 homeobox 1 
(POU5F1, OCT3/4), sex-determining region Y-box 2 (SOX2), Kruppel-like factor 4 (gut) 
(KLF4) and v-myc myelocytomatosis viral oncogene homologue (avian) (MYC, c-Myc) 
induce fibroblast reprogramming into pluripotent stem cells (Takahashi et al., 2007; Park et 
al., 2008; Lowry et al., 2008). After determining that reprogramming genes actually exist to 
manipulate and modify human cells, these 4 genes, or some other set of genes such as 
POU5F1 (OCT4), SOX2 and KLF4 have been used globally to produce induced pluripotent 
stem cells. 
Recently, somatic cells have been suggested to be directly reprogrammed without an 
induced pluripotent stem cell-mediated pathway but with culture condition modifications 
(Han et al, 2011). In that study, fibroblasts were infected with retrovirus expressing Oct4, 
Sox2, Klf4 and c-Myc, and directly induced into epiblast stem cells by adding basic fibroblast 
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growth factor. The combination of gene expression and factors from outside the cells may 
play important roles in reprogramming cells. 
4.1 Genes for generation of induced pluripotent stem (iPS) cells 
Recently, it had been reported that OCT4 is sufficient to induce alterations in the human 
keratinocyte differentiation pathway (Racila et al., 2011). Transfection of OCT4, using a 
plasmid, into human skin keratinocytes resulted in exhibited expression of endogenous 
embryonic genes and reduced genomic methylation. These OCT4-transfected cells could 
become neuronal and mesenchymal cell types. The cells have been shown to have 
characteristics of cultured smooth muscle or myofibroblast cells from a mesenchymal stem 
cell lineage. It is probable that partial reprogramming using several genes can induce 
transitions in cell phenotypes and features; hence, complete reprogramming of somatic cells 
into iPS cells would not always be required for the application of these cells in clinical 
therapy. 
The characterization of human iPS cells, with respect to pluripotency and the ability for 
terminal differentiation, has been performed with 16 iPS cell lines (Boulting et al., 2011). This 
study revealed that all iPS cell lines examined, reprogrammed with OCT4, SOX2 and KLF4, 
or OCT4, SOX2, KLF4 and c-MYC showed the capacity to function as functional motor 
neurons after differentiation, although there was some variation in the expression of early 
pluripotency markers and the transgenes. iPS cell lines have been shown to express 
pluripotency markers, such as NANOG, OCT4, SSEA3, SSEA4, TRA-1-60 and TRA-1-81. 
4.2 Involvement of genome structure in reprogramming to iPS cells 
Copy number variation has been reported to be involved in the reprogramming to 
pluripotency (Hussein et al., 2011). The comparison of copy number variations of different 
passages of human iPS cells with their fibroblast cell origins and with human embryonic 
stem (ES) cells revealed high copy number variation levels in early-passage human iPS cells. 
The number of copy number variations in human iPS cell lines decreases with an increase in 
the number of passage. This decrease during culture passages could be due to DNA repair 
mechanisms or mosaicism followed by selection. The authors proposed that de novo 
generated copy number variations create mosaicism that is followed by selection of less 
damaged cells during culturing, because DNA repair is not considered as a sufficient 
explanation of the rapid decrease in copy number variation. 
4.3 Involvement of epigenetic modification and methylation in iPS cells 
EMT has been shown to be associated with a stem cell phenotype (Mani et al., 2008; Battula 
et al., 2010; Polyak & Weinberg, 2009). The tumour suppressor p53 has been suggested to 
regulate EMT and EMT-associated stem cell properties through transcriptional activation of 
miRNA (Chang et al., 2011). EMT and the reverse process, the mesenchymal-epithelial 
transition, are believed to be key elements in the regulation of embryogenesis. It has also 
been suggested that EMT activation is related to cancer progression and metastasis.  
Recently, EMT has been shown to play a role in the acquisition of stem cell properties in 
normal and neoplastic cell populations. miRNAs are small non-coding RNA molecules and 
suppress gene expression by interacting with the 3’-untranslated regions (3’ UTRs) of target 
mRNAs. miRNAs are known to be related to EMT and cancer. The study revealed that p53 
activates miR-200c, which is down-regulated in normal stem cell and neoplastic stem cell 
populations, and suppresses the EMT phenotype and stem cell properties represented in 
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CD24−CD44+ cell populations. The expression of mesenchymal stem cell markers, such as 
N-cadherin and ZEB1, has been shown to be suppressed by p53. The mRNA levels of KLF4 
and BMI1, which are known as stemness-associated genes and RNA targets of miR-200c and 
miR-183, have been shown to be regulated by p53. 
It has also been reported that the p53R175H mutant up-regulates Twist1 expression and 
promotes EMT in immortalized prostate cells (Kogan-Sakin et al., 2011). Inactivated or 
mutated p53 may result in the up-regulation of cell cycle progression genes, such as Twist1, 
which is a regulator of metastasis and EMT. 
4.4 Epithelial-mesenchymal transition (EMT) and microRNAs (miRNAs) 
iPS cells have been known to show reprogramming variability such as aberrant 
reprogramming of DNA methylation (Lister et al., 2010). From whole-genome, single-base-
resolution DNA methylomic analyses of iPS cells and ES cells, the authors obtained new 
evidence showing that iPS cells are methylated during reprogramming, and the methylome 
of iPS cells generally resembles that of ES cells. In the study, a detailed interpretation of the 
data indicated that there were many differences in DNA methylation between ES cells and 
iPS cells. For example, many differentially methylated regions that were differentially 
methylated in either the iPS cell line or the ES cell line existed in several iPS cell lines. 
5. Gene markers for cancer cells 
5.1 Regulated genes in renal cancer 
NCBI’s Gene Expression Omnibus (GEO) database is a useful tool to profile gene expression 
and search for markers representing cell features (Edgar et al., 2002; Barrett, 2011). Renal 
tumour samples have been analysed using microarray (Yusenko et al., 2009). It was 
observed that loss of chromosomes 2, 10, 13, 17 and 21 discriminate chromophobe renal cell 
carcinomas from renal oncocytomas. These authors suggested that detecting chromosomal 
changes can be used for an accurate diagnosis in routine histology. 
The gene expression profiles of the microarray data deposited in the GEO database (GEO 
series, Szponar et al., 2009, accession GSE11151) were analysed and caveolin 2 (CAV2), 
proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) 
(PSMB8) major histocompatibility complexes, class I, F (HLA-F), major histocompatibility 
complex, class I, B (HLA-B), apoptosis enhancing nuclease (AEN), major histocompatibility 
complex, class I, G (HLA-G), and tumour necrosis factor receptor superfamily member 10b 
(TNFRSF10B) are upregulated by more than three-fold in renal tumours (n = 62) compared 
to normal kidney (n = 5) (Table 3). 
The collaborative genome-wide study for renal cell carcinoma using SNP detection 
techniques has revealed that genome loci on 2p21 and 11q13.3 are genomic regions 
associated with renal cell carcinoma (Purdue et al., 2011). From this study, EPAS1, encoding 
hypoxia-inducible-factor-2 alpha at 2p21 and SCARB1, the scavenger receptor class B, 
member 1 at 12q24.31, were identified as feature genes that have single nucleotide 
polymorphism mutations in renal cell carcinoma. 
5.2 Genes expressed in leukaemia 
A model in which human cancers are believed to be generated hierarchically from self-
renewing cancer stem cells has been reported. Human acute myeloid leukaemia (AML) is a 
disease that relates to the model, and AML stem cell-targeting therapy has been developed 
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(Majeti, 2011; Jin et al., 2006). CD25, CD32, CD44, CD47, CD96, CD123 and CLL-1 are 
expressed on the surface of AML stem cells. Of these genes, CD44 is suggested to be a cancer 
stem cell marker. 
 
Gene 
Symbol 
Gene Title 
Chromosomal 
location 
Entrez Gene Function 
CAV2 Caveolin-2 Chr7q31.1 858 
Protein 
homodimerisati
on activity 
PSMB8 
Proteasome (prosome, 
macropain) subunit, 
beta type, 8 (large 
multifunctional 
peptidase 7) 
Chr6p21.3 5696 
ATP binding, 
MHC class I 
protein binding 
HLA-F 
Major 
histocompatibility 
complex, class I, F 
Chr6p21.3 3134 
MHC class I 
receptor 
activity 
HLA-B 
Major 
histocompatibility 
complex, class I, B 
Chr6p21.3 3106 
MHC class I 
receptor 
activity 
AEN 
Apoptosis enhancing 
nuclease 
Chr15q26.1 64782 
Exonuclease 
activity 
HLA-G 
Major 
histocompatibility 
complex, class I, G 
Chr6p21.3 3135 
MHC class I 
receptor 
activity 
TNFRSF10B 
Tumour necrosis 
factor receptor 
superfamily,  
member 10b 
Chr8p22-p21 8795 
TRAIL binding, 
caspase 
activator 
activity 
 
Table 3. Upregulated genes in renal tumours (Ref. GSE11151) 
The concept of cancer stem cell is important in explaining cancer development from the 
viewpoint of stem cells (Clevers, 2011; Wang & Shen, 2011). The cancer stem cells for 
leukaemia were identified from a study showing that CD34+CD38− fractions of cells 
derived from acute myeloid leukaemia had the capacity to initiate engraftment in 
immunodeficient mice (Lapidot et al., 1994; Bonnet & Dick, 1997). It is known that deletion 
or mutation of IKZF1 (IKAROS), PAX5, EBF1 and CDKN2A/B are involved in BCR-ABL1 
lymphoblastic leukaemia (Mullighan et al., 2008; Mullighan et al., 2009).  
The function of human BCR-ABL1 lymphoblastic leukaemia-initiating cells in human 
lymphoblastic leukaemia has been studied from the point of view of genome diversity 
(Notta et al., 2011). Functional and genetic analysis of Philadelphia chromosome acute 
lymphoblastic leukaemia (Philadelphia-positive [Ph+] ALL) revealed that the frequencies of 
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genetic alterations in IKZF1 (84%), CDKN2A/B (50%) and PAX5 (50%) were consistent with 
those reported in previous studies. Complete deletion of IKZF1 was observed in both 
aggressive and non-aggressive groups; whereas, there were differences in the frequencies of 
deletion of the CDKN2A/B and PAX5 genes, which may provide markers for malignancy. 
On the other hand, CD44 has been identified as a key regulator of leukaemic stem cells in 
AML (Jin et al., 2006). It was suggested that elimination of leukaemic stem cells, cells 
capable of initiating and maintaining the leukaemic clonal hierarchy, was required for a 
permanent cure of AML. Hence, stimulation with a CD44-specific antibody has been 
reported to result in the elimination of leukaemic stem cells. 
5.3 Genes expressed in glioblastomas 
Wang et al. hypothesised that the CD133+ fraction is related to the endothelial differentiation 
potential and analysed cells from a series of glioblastomas fractionated as follows:  
(1) CD144+ (endothelial cadherin)/CD133−, (2) CD144+/CD133+, (3) CD133+/CD144−,  
(4) CD133−/CD144−. The results of quantitative PCR with a reverse transcription analysis 
demonstrated that VEGFR2 and endothelial progenitor marker CD34 are enriched in the 
CD144+/CD133− and in the CD144+/CD133+ populations. CD105 was negative in the 
CD133+ and CD144+ fractions. It was also shown that mice who were administered an 
injection of CD133+/CD144− or CD133+/CD144+ cells from a primary glioblastoma 
revealed tumours. 
A new mechanism was suggested in which tumour vascularisation occurs through 
endothelial differentiation of glioblastoma stem-like cells (Ricci-Vitiani et al., 2010). The 
differentiation of cancer stem-like cells may be involved in cancer malignancy, and it is 
possible to predict or diagnose the malignant stage of cancer using stem cell markers for 
quality control. 
In a genome-wide association study (GWAS) of four case series on 2,251 test patients and 
6,097 control patients of European ancestry, LIM domain only 1 (LMO1) at 11p15.4 was 
found to be associated with neuroblastoma and malignancy (Wang et al., 2011). An 
integrative genomics study to demonstrate that common genetic polymorphisms associated 
with cancer tendencies are also related to genomic regions that have possibility of somatic 
alterations which in turn influence tumour progression, revealed that mutation in LMO1 
may also be a candidate indicator of a malignant phenotype. 
5.4 Surface markers for cancer stem cells 
Several markers have been reported for identification of cancer stem cells (Clevers, 2011). 
CD19 as a surface marker for B cell malignancies, CD20 and ATP-binding cassette 
transporter B5 (ABCB5) for melanoma, and the following molecules for cancer stem cells in 
the respective cancer type have been reported: CD24 for pancreas/lung cancer, CD34 for 
hematopoietic malignancies, CD44 for breast/liver/head and neck/pancreas cancer, CD90 
for liver cancer, CD133 for brain/colorectal/lung/liver cancer and epithelial cell adhesion 
molecule (EpCAM)/epithelial-specific antigen (ESA) for colorectal/pancreatic cancer 
(Ebben et al., 2010). 
5.5 Cancer stem cell hypothesis 
Cancer stem cells have capacity for self-renewal, which is also the feature to normal stem 
cells. Cancer stem cells are also capable of generating malignant tumours, and this property 
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may differentiate them from normal stem cells. The origin of the cancer stem cells has not 
been fully revealed, however, there is a model in which cancer stem cells occur by normal 
stem cells or normal cells by the accumulation of gene mutations. The process of cancer stem 
cell derivation is considered to be involved with niche which is microenvironment around 
normal stem cells.  
There are two models to explain tumourigenesis. The first model is stochastic model in 
which all cells have capacity of tumourigenesis, but the probability to enter into 
tumourigenesis cell cycle is relatively low. The second model is hierarchy theory in which 
only small population of cells in cancer has capacity of tumourigenesis and generate tumour 
with high probability, which lead to cancer stem cell hypothesis. 
It is also notable that cancer stem cells are not necessarily related to the cell of origin in a 
cancer (Visvader, 2011). Although the cell of origin for a particular tumour may have the 
capacity to differentiate into a mature cell, cancer stem cells have the ability to maintain 
tumourigenesis according to the cell-of-origin model. 
6. Conclusion 
The recent development in molecular biology and bioinformatics technology has revealed 
stem cell features and their candidate marker genes. Gene expression profiles change widely 
and dramatically with cell development, various culture conditions and disease status. The 
each cell type has different gene expression profile after being differentiated, and it is 
known that the expression pattern alters in each disease status. Even though it seems that 
the stemness has distinct feature in gene expression, the cell population show various gene 
expression patterns in each cell lineage or even in each subset of the cell.  
Until recently, targeting cancer stem cells in cancer therapy was rare because the proportion 
of these cells in cancer was considered very low and retaining the feature of cancer stem 
cells in vitro was difficult. The stem cell-targeted therapy including cancer treatment will be 
expected to progress further in the near future, and the role of markers would become much 
greater. It is important to know the precise feature and gene expression pattern for quality 
control in the cell-targeted therapy. 
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